Sensus Healthcare (NASDAQ:SRTS) Trading Down 0.3% – Here’s What Happened

Sensus Healthcare, Inc. (NASDAQ:SRTS) shares traded down 0.3% on Monday . The stock traded as low as $3.00 and last traded at $3.02. Approximately 30,645 shares were traded during trading, an increase of 39% from the average daily volume of 22,123 shares. The stock had previously closed at $3.03.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SRTS. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Price Performance

The company’s fifty day moving average price is $2.97 and its 200 day moving average price is $3.83. The company has a market cap of $49.72 million, a PE ratio of -6.43 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The firm had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Greenline Wealth Management LLC purchased a new stake in Sensus Healthcare in the 4th quarter worth about $513,000. North Star Investment Management Corp. purchased a new stake in Sensus Healthcare during the first quarter valued at about $500,000. Rothschild Wealth LLC purchased a new stake in Sensus Healthcare during the fourth quarter valued at about $500,000. Pacific Ridge Capital Partners LLC boosted its position in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after purchasing an additional 125,245 shares during the period. Finally, Ingalls & Snyder LLC bought a new position in Sensus Healthcare during the fourth quarter worth about $219,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.